"Optimal Pricing, Purchasing, and Co-Development with Applications in Public and Private Sector Pharmaceutical Management"

“优化定价、采购和共同开发及其在公共和私营部门药品管理中的应用”

基本信息

批准号：
228649-2012
负责人：
Zaric, Gregory
金额：
$ 2.04万
依托单位：
University of Western Ontario
依托单位国家：
加拿大
项目类别：
Discovery Grants Program - Individual
财政年份：
2013
资助国家：
加拿大
起止时间：
2013-01-01 至 2014-12-31
项目状态：
已结题

来源：
https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=524219
关键词：
Optimal Pricing Purchasing Co Development

项目摘要

I will investigate a number of issues related to optimal purchasing contracts, optimal pricing, and optimal co-development opportunities, all of which are motivated by management problems in the pharmaceutical and biotechnology industries. These topics (pricing, purchasing and co-development) are closely related and tied together by the following trends: 1. The use of cost-effectiveness or net benefits analysis as a criteria for drugs to be listed on formularies; 2. The increasing use of "risk sharing" contracts between drug purchasers, such as government insurance plans, and drug manufacturers; 3. The development of very expensive drugs which are only effective for a portion of the population; and 4. The promise of genetic tests to help identify, and thus target, those who are most likely to benefit from new targeted therapies. These trends lead to a number of challenging management problems for managers of public sector drug plans, as well as manufacturers of drugs and genetic tests. In this research I will develop operations research models to help gain insight into these problems. Note that the focus of this research is not on the clinical or basic science issues underlying these trends but rather on the development of mathematical models to address the management issues, in both the public and private sector, that arise from these trends.

我将研究许多与最佳购买合同，最佳定价和最佳共同开发机会有关的问题，所有这些问题都是由药物和生物技术行业中的管理问题激发的。这些主题（定价，采购和共同开发）与以下趋势密切相关，并将其捆绑在一起：1。使用成本效益或净福利分析作为在配方式上列出的药物的标准； 2。毒品购买者（例如政府保险计划和毒品制造商）之间越来越多地使用“风险共享”合同； 3。开发非常昂贵的药物，仅对部分人口有效；和4。基因检测的希望有助于识别最有可能受益于新的靶向疗法的人。这些趋势导致了公共部门药物计划的管理者以及药物和基因检测的制造商的许多具有挑战性的管理问题。在这项研究中，我将开发运营研究模型，以帮助了解这些问题。请注意，这项研究的重点不在这些趋势的临床或基础科学问题上，而是在数学模型的发展上，以解决这些趋势引起的公共和私营部门的管理问题。